Asset Advisors Investment Management’s AbbVie ABBV Stock Holding History

Asset Advisors Investment Management’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$23.8M	Sell	94,611 -1,214	-1%	-$261K	2.18%	14
2026 Q1	$20.8M	Sell	95,825 -262	-0.3%	-$58.1K	1.99%	16
2025 Q4	$22M	Buy	96,087 +39	+0%	+$8.88K	2.03%	16
2025 Q3	$22.2M	Buy	96,048 +1,507	+2%	+$307K	2.11%	15
2025 Q2	$17.5M	Sell	94,541 -137	-0.1%	-$25.5K	1.73%	18
2025 Q1	$19.8M	Sell	94,678 -400	-0.4%	-$77.8K	2.08%	16
2024 Q4	$16.9M	Sell	95,078 -2,245	-2%	-$413K	1.77%	19
2024 Q3	$19.2M	Sell	97,323 -495	-0.5%	-$92.4K	2%	14
2024 Q2	$16.8M	Buy	97,818 +5,417	+6%	+$897K	1.83%	17
2024 Q1	$16.8M	Buy	92,401 +2,982	+3%	+$514K	1.89%	17
2023 Q4	$13.9M	Buy	89,419 +799	+0.9%	+$116K	1.69%	21
2023 Q3	$13.2M	Sell	88,620 -1,067	-1%	-$157K	1.78%	18
2023 Q2	$12.1M	Sell	89,687 -2,650	-3%	-$389K	1.54%	22
2023 Q1	$14.7M	Buy	92,337 +92	+0.1%	+$14.1K	1.93%	17
2022 Q4	$14.9M	Sell	92,245 -600	-0.6%	-$92K	1.96%	16
2022 Q3	$12.5M	Sell	92,845 -225	-0.2%	-$32.3K	1.78%	17
2022 Q2	$14.3M	Sell	93,070 -3,550	-4%	-$542K	1.94%	15
2022 Q1	$15.7M	Buy	96,620 +4,225	+5%	+$614K	1.75%	20
2021 Q4	$12.5M	Sell	92,395 -3,700	-4%	-$437K	1.26%	27
2021 Q3	$10.4M	Sell	96,095 -13,485	-12%	-$1.54M	1.16%	29
2021 Q2	$12.3M	Buy	109,580 +2,000	+2%	+$225K	1.37%	26
2021 Q1	$11.6M	Sell	107,580 -50	-0%	-$5.35K	1.35%	26
2020 Q4	$11.5M	Buy	107,630 +4,918	+5%	+$473K	1.49%	23
2020 Q3	$9M	Sell	102,712 -2,702	-3%	-$254K	1.36%	24
2020 Q2	$10.3M	Sell	105,414 -1,366	-1%	-$120K	1.65%	19
2020 Q1	$8.14M	Sell	106,780 -2,230	-2%	-$190K	1.51%	24
2019 Q4	$9.62M	Buy	109,010 +8,990	+9%	+$746K	1.4%	24
2019 Q3	$7.57M	Buy	100,020 +2,075	+2%	+$142K	1.21%	28
2019 Q2	$7.12M	Buy	97,945 +855	+0.9%	+$67.2K	1.2%	29
2019 Q1	$7.82M	Buy	97,090 +350	+0.4%	+$28.6K	1.39%	23
2018 Q4	$8.92M	Buy	96,740 +1,430	+2%	+$126K	1.77%	18
2018 Q3	$9.01M	Buy	+95,310	New	+$9.04M	1.49%	21

Other funds holding ABBV

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

ATO

Alecta Tjanstepension Omsesidigt Stockholm, Sweden $23.8B AUM 34.25% 1-Year Est. Return

New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

HCM

Hamlin Capital Management New York $4.45B AUM 22.95% 1-Year Est. Return

AAMU

AEGON Asset Management (UK) Edinburgh, United Kingdom $9.38B AUM 48.94% 1-Year Est. Return

FWCM

Ferguson Wellman Capital Management Portland, Oregon $8.19B AUM 30.56% 1-Year Est. Return

AAIS

ABN AMRO Investment Solutions Paris Cedex 008 $11.5B AUM 32.2% 1-Year Est. Return

Asset Advisors Investment Management's ABBV Position: Q2 2026 in Review

Asset Advisors Investment Management reduced its AbbVie (ABBV) stake by 1.3% in Q2 2026, selling an estimated $261K and leaving 94,611 shares worth $23.8M. The position accounts for 2.18% of the portfolio, ranked #14.

Asset Advisors Investment Management first reported a position in ABBV in Q3 2018 and has held it in 32 quarters since. 1,602 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Asset Advisors Investment Management held 94,611 shares of AbbVie worth $23.8M as of Q2 2026.
Asset Advisors Investment Management sold 1,214 AbbVie shares in Q2 2026, an estimated $261K.
AbbVie made up 2.18% of Asset Advisors Investment Management's portfolio in Q2 2026, its #14 holding.
Asset Advisors Investment Management first reported a position in AbbVie in Q3 2018 and has held it in 32 quarters since.
1,602 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Asset Advisors Investment Management's 13F filing for Q2 2026, filed 22 Jul 2026.